0001493152-22-027755.txt : 20221006 0001493152-22-027755.hdr.sgml : 20221006 20221006070150 ACCESSION NUMBER: 0001493152-22-027755 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20221004 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20221006 DATE AS OF CHANGE: 20221006 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Provention Bio, Inc. CENTRAL INDEX KEY: 0001695357 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38552 FILM NUMBER: 221297087 BUSINESS ADDRESS: STREET 1: 55 BROAD STREET, 2ND FLOOR CITY: RED BANK STATE: NJ ZIP: 07701 BUSINESS PHONE: 908-428-9136 MAIL ADDRESS: STREET 1: 55 BROAD STREET, 2ND FLOOR CITY: RED BANK STATE: NJ ZIP: 07701 FORMER COMPANY: FORMER CONFORMED NAME: Provention Inc. DATE OF NAME CHANGE: 20170120 8-K 1 form8-k.htm
0001695357 false 0001695357 2022-10-04 2022-10-04 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of report (Date of earliest event reported): October 4, 2022

 

Provention Bio, Inc.

(Exact Name of Registrant as Specified in Charter)

 

Delaware   001-38552   81-5245912

(State or Other Jurisdiction

of Incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

 

55 Broad Street, 2nd Floor

Red Bank, NJ

   07701
(Address of Principal Executive Offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (908) 336-0360

 

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common stock, $0.0001 par value per share   PRVB   The Nasdaq Global Select Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

Item 1.01 Entry into a Material Definitive Agreement.

 

Co-Promotion Agreement

 

On October 4, 2022, the Company and Genzyme Corporation, a fully-owned subsidiary of Sanofi (“Sanofi”) entered into a Co-Promotion Agreement (the “Sanofi Co-Promotion Agreement”). Pursuant to the Sanofi Co-Promotion Agreement, the Company appointed Sanofi to co-promote and conduct certain commercialization activities with respect to teplizumab in the United States on a co-exclusive basis for the treatment of the indication for which teplizumab receives approval in the United States during the term of the Sanofi Co-Promotion Agreement. Under the Sanofi Co-Promotion Agreement, Sanofi commits to making field resources representing more than 100 FTEs available for such co-promotion and commercialization activities if teplizumab is approved in the United States by a certain date.

 

Pursuant to the Sanofi Co-Promotion Agreement, the Company commits to reimburse the field force-related expenses and certain other allowable expenses that Sanofi will incur in connection with commercializing teplizumab under the agreement, up to an aggregate cap of $33 million, which includes a pre-determined margin on field force-related expenses.

 

Pursuant to the Sanofi Co-Promotion Agreement, the Company also granted Sanofi an exclusive, one-time right of first negotiation to obtain exclusive rights to research, develop and commercialize teplizumab with respect to the treatment or delay of Type 1 diabetes, or any of its root causes throughout the world, and to manufacture teplizumab in support of such research, development and commercialization (the “ROFN”) in exchange for a one-time upfront payment of $20 million, and subject to certain retained rights of the Company to engage in discussions with third parties with respect to certain transactions (“Third Party Transactions”). Sanofi may exercise the ROFN beginning on October 4, 2022 until June 30, 2023 (the “Initial ROFN Period”), and the Initial ROFN Period may be extended (a) at Sanofi’s election, upon payment of a one-time extension fee, to the later of (i) September 30, 2023, and (ii) 60 days after the Company delivers to Sanofi the top-line data for an identified clinical trial sponsored by the Company (the “Data Delivery Date”); or (b) automatically, without an extension fee, to 60 days after the Data Delivery Date if the Company does not receive regulatory approval for teplizumab before November 30, 2022. Within six months following the later of the expiration of (x) the Initial ROFN Period, and (y) any extension to the Initial ROFN Period pursuant to the terms of the Sanofi Co-Promotion Agreement, the Company may not enter into a Third Party Transaction on terms that are materially less favorable in the aggregate to the Company than the most recent terms Sanofi offered, if any, without first permitting Sanofi to execute an agreement with the Company on either such terms previously offered by Sanofi or the terms offered by such third party.

 

The activities of the Company and Sanofi under the Sanofi Co-Promotion Agreement in the United States will be overseen by a joint steering committee composed of representatives from the Company and Sanofi. Under the Sanofi Co-Promotion Agreement, subject to any execution of a definitive agreement following an exercise of the ROFN (as defined below), the Company will retain the right to develop, manufacture, supply and distribute, as well as determine the commercialization strategy for, teplizumab and will remain responsible for the costs of holding and maintaining regulatory approval of, reporting adverse events relating to, developing, manufacturing, supplying and distributing teplizumab.

 

The term of the Sanofi Co-Promotion Agreement expires on December 31, 2023. Subject to specified notice periods and limitations, (a) Sanofi may terminate the Sanofi Co-Promotion Agreement early if regulatory approval for teplizumab either is not obtained in the U.S. by December 31, 2022 or is obtained but later withdrawn or the Company undergoes a change of control with a major biopharmaceutical company with a certain level of financial resources and (b) either the Company or Sanofi may terminate the Sanofi Co-Promotion Agreement early if (i) the other party commits an uncured material breach, (ii) the other party undergoes a bankruptcy event, (iii) there is a material safety event associated with teplizumab, or (iv) there is a prolonged delay in performance due to a force majeure event.

 

Securities Purchase Agreement

 

Simultaneously with their entry into the Sanofi Co-Promotion Agreement, the Company and Sanofi also entered into a Securities Purchase Agreement (the “Purchase Agreement”). Pursuant to the Purchase Agreement, if the Biologics License Application submitted to the United States Food and Drug Administration (the “FDA”) for the delay of clinical type 1 diabetes in at-risk individuals is approved by the FDA, Sanofi has agreed to purchase $35 million of the Company’s common stock, par value $0.0001 per share (the “Common Stock”). The purchase price per share will equal 140% of the daily volume-weighted average per share price of the Common Stock for the five consecutive trading days prior to the closing date. The closing date and five consecutive trading day period for determining the purchase price per share shall be at the Company’s election, but the closing must occur no later than February 16, 2023.

 

 

 

 

Pursuant to the Purchase Agreement, prior to June 30, 2023 (the “Lock-Up Period”) Sanofi will not, without the prior written consent of the Company, directly or indirectly, (i) offer, pledge, sell, contract to sell, sell any shares of Common Stock, or otherwise dispose of or transfer any Shares (collectively, the “Lock-Up Securities”) or (ii) enter into any swap or any other agreement or any transaction that transfers, in whole or in part, directly or indirectly, the economic consequence of ownership of the Lock-Up Securities, whether any such swap or transaction is to be settled by delivery of Common Stock or other securities, provided, that the foregoing shall not prohibit (a) Sanofi from transferring any Lock-Up Securities to any of its affiliates or to the Company, (b) the disposition of any Lock-Up Securities pursuant to (x) any merger, consolidation or similar transaction to which the Company is a constituent corporation or (y) a bona fide tender offer or exchange offer made to all holders of Common Stock by a person other than the Sanofi or any of Sanofi’s affiliates, or (c) Sanofi from transferring shares of Common Stock to reduce its ownership below 19.9% if the Common Stock owned by Sanofi represents greater than 19.9% ownership of the then-outstanding shares of Common Stock solely as a result of an action taken by the Company.

 

The Purchase Agreement also provides Sanofi with demand registration rights in respect of the shares of Common Stock issued pursuant to the Purchase Agreement, subject to certain conditions. In addition, in the event that the Company registers additional shares of common stock for sale to the public, the Company will be required to give notice of such registration to Sanofi, and, subject to certain limitations, include Sanofi’s shares of Common Stock in such registration. The registration rights granted under the Purchase Agreement will commence on June 30, 2023 and expire on June 30, 2025.

 

The foregoing is a summary description of certain terms of the Sanofi Co-Promotion Agreement and the Purchase Agreement are not complete and are qualified in its entirety by reference to the text of the Sanofi Co-Promotion Agreement and the Purchase Agreement, which the Company expects to file as exhibits to the Company’s Annual Report on Form 10-K for the fiscal ending December 31, 2022.

 

Item 7.01 Regulation FD Disclosure.

 

On October 6, 2022, the Company issued a press release announcing the entry into the Sanofi Co-Promotion Agreement and the Purchase Agreement. A copy of the press release is furnished herewith as Exhibit 99.1 and incorporated herein by reference.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) The following exhibit is furnished with this report:

 

Exhibit No.   Description
     
99.1   Press Release issued by Provention Bio, Inc. on October 6, 2022
     
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  Provention Bio, Inc.
     
Dated: October 6, 2022 By: /s/ Thierry Chauche
    Thierry Chauche
    Chief Financial Officer

 

 

 

 EX-99.1 2 ex99-1.htm

 

Exhibit 99.1

 

 



Provention Bio to Combine Forces with Sanofi to Support Potential U.S. Launch of Teplizumab for Delay in Onset of Clinical Type 1 Diabetes (T1D) in At-Risk Individuals

 

● Provention receives $20 million nonrefundable payment granting Sanofi exclusive right of first negotiation to in-license teplizumab globally for T1D
● U.S. copromotion agreement leverages Sanofi’s in-market infrastructure and established expertise in endocrinology to expand reach, increase awareness and drive T1D screening
● Sanofi to invest $35 million at a premium after a potential teplizumab FDA approval
● Investor Conference call at 8:30am ET Today

 

RED BANK, N.J., October 6, 2022 /PRNewswire/ — Provention Bio, Inc. (Nasdaq: PRVB) (the “Company”), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced that the Company has entered into a co-promotion agreement with Sanofi U.S. for the launch of Provention’s lead investigational drug candidate teplizumab. The agreement enables Provention Bio to leverage Sanofi’s expertise, capabilities and commercial resources to support the potential launch of teplizumab currently under review by the U.S. Food and Drug Administration (“FDA”), for the delay of clinical type 1 diabetes in at-risk individuals, with a user fee goal date of November 17, 2022 for the Biologics License Application.

 

“This collaboration with Sanofi U.S. allows us to significantly expand our planned commercial footprint during launch to support increased screening and product awareness as we work to launch a new therapy that, if approved, will dramatically impact the lives of the patients and families we serve,” said Jason Hoitt, Chief Commercial Officer, Provention Bio. “In particular, Sanofi’s long-standing relationships with key U.S. healthcare professionals will complement our focus on pediatric endocrinologists and help us address a larger patient population with greater efficiency.”

 

 
 

 

Olivier Bogillot, Head of U.S. General Medicines, Sanofi, stated, “We are delighted by the prospect of supporting Provention Bio in bringing to the U.S. what could become the first-in-class therapy to change the course of type 1 diabetes. If approved, Sanofi U.S. will leverage its existing world-class capabilities in diabetes care to enhance efforts in both patient and healthcare provider access. We are prepared to tap into all of our internal expertise to support the successful launch of this innovative therapy.”

 

“The agreement brings significant resources to Provention and allows us to advance our mission of delivering therapies which intercept or delay debilitating and life-threatening autoimmune diseases,” said Ashleigh Palmer, Co-Founder and Chief Executive Officer, Provention Bio. “We look forward to working with our colleagues at Sanofi as we prepare to deliver, if approved, the first-ever disease-modifying therapy for T1D.”

 

Co-Promotion Agreement

 

Under the terms of the agreement, Sanofi will commit commercial resources in the United States, including diabetes field specialists, account directors, field-based reimbursement and medical science liaisons to expand the number of key healthcare professionals reached in the United States. In exchange, Provention will reimburse field force-related expenses that Sanofi will incur in connection with commercializing teplizumab under the agreement.

 

Provention retains all rights to teplizumab and maintains responsibility for the commercialization strategy.

 

Right of First Negotiation to Global Commercial Rights

 

The Company also granted Sanofi, in consideration of a one-time payment of $20 million, an exclusive, one-time right of first negotiation (ROFN) to obtain exclusive global rights to commercialize teplizumab for Type 1 diabetes indications in humans, subject to certain retained rights of the Company to engage in discussions with third parties with respect to certain transactions. Sanofi may exercise the ROFN, until June 30, 2023, with an option to extend within 2023 under certain conditions.

 

Equity Investment

 

Simultaneous with their entry into the co-promotion agreement, the Company and Sanofi entered into a Securities Purchase Agreement (the “Purchase Agreement”). Pursuant to the Purchase Agreement, if teplizumab is approved by the FDA, Sanofi has agreed to purchase $35 million of the Company’s common stock at a premium over the daily volume-weighted average per share price for the five consecutive trading days prior to the closing date. The closing date will be at Provention’s discretion and would occur no later than February 16, 2023.

 

 
 

 

BofA Securities acted as financial advisor to the Company on this transaction.

 

For important information related to the terms of the Co-Promotion Agreement and Securities Purchase Agreement, see Provention Bio’s Current Report on Form 8-K filed with the Securities and Exchange Commission on October 6, 2022.

 

Conference Call and Webcast Information

 

Provention Bio will discuss this business update via conference call today at 8:30 am ET. To access the call, please dial 1-888-347-7861 (domestic) or 1-412-902-4247 (international) ten minutes prior to the start time and ask to be connected to the “Provention Bio Call.” An audio webcast will also be available on the “Events and Webcasts” page of the Investors section of the Company’s website, www.proventionbio.com. An archived webcast will be available on the Company’s website approximately two hours after the conference call.

 

About Teplizumab

 

Teplizumab is an anti-CD3 monoclonal antibody that is being developed for the delay of clinical T1D in at-risk individuals, as indicated by the presence of two or more T1D-related autoantibodies. There has been no disease-modifying innovation for this life-impacting and life-threatening autoimmune disease since the development of insulin a century ago. More than 800 patients have received teplizumab in multiple clinical studies involving more than 1,000 subjects. Provention is currently also evaluating teplizumab in patients with newly diagnosed insulin-dependent T1D (the Phase 3 PROTECT study).

 

About Provention Bio, Inc.

 

Provention Bio, Inc. (Nasdaq: PRVB) is a biopharmaceutical company focused on advancing the development of investigational therapies that may intercept and prevent debilitating and life-threatening immune-mediated diseases. The Biologics License Application (BLA) for teplizumab, its lead investigational drug candidate, for the delay of progression to Stage 3 clinical type 1 diabetes in at-risk individuals has been filed by the U.S. Food and Drug Administration (FDA). The Company’s pipeline includes additional clinical-stage product candidates that have demonstrated in pre-clinical or clinical studies proof-of-mechanism and/or proof-of-concept in other autoimmune diseases, including celiac disease and lupus. Visit www.ProventionBio.com for more information and follow us on Twitter: @ProventionBio.

 

Internet Posting of Information

 

Provention Bio, Inc. uses its website, www.proventionbio.com, as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation F.D. Such disclosures will be included on the Company’s website in the “News” section. Accordingly, investors should monitor this portion of the Company’s website, in addition to following its press releases, SEC filings and public conference calls and webcasts.

 

 
 

 

Forward-Looking Statements

 

Certain statements in this press release are forward-looking, including but not limited to, statements relating to the Company’s ability to leverage Sanofi’s expertise, capabilities and commercial resources to support the potential launch of teplizumab, the potential that the collaboration with Sanofi to significantly expand the Company’s planned commercial footprint during launch, the potential exercise of the ROFN by Sanofi, the potential approval and commercialization of teplizumab and the potential closing of the common stock offering to Sanofi. These statements may be identified by the use of forward-looking words such as “may” and “potential,” among others. These forward-looking statements are based on the Company’s current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, risks related to FDA disagreeing with the Company’s interpretation of data and analysis and information in the BLA resubmission; delays in or failure to obtain FDA approvals for teplizumab or other Company product candidates and the potential for noncompliance with FDA regulations; any inability to successfully work with FDA to address its concerns and requests in a timely manner or at all during the review process for teplizumab, including any inability to provide the FDA with data, analysis or other information sufficient to support an approval of the BLA for teplizumab; any inability to satisfactorily address matters related to PK comparability, product quality, safety or any other FDA requirements during the BLA review process to obtain an approval of teplizumab; the potential impacts of COVID-19 on our business and financial results; changes in law, regulations, or interpretations and enforcement of regulatory guidance; uncertainties of patent protection and litigation; the Company’s dependence upon third parties; substantial competition; the Company’s need for additional financing and the risks listed under “Risk Factors” in the Company’s quarterly report on Form 10-Q for the quarter ended June 30, 2022 and any subsequent filings with the Securities and Exchange Commission. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. Provention does not undertake an obligation to update or revise any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by applicable law. The information set forth herein speaks only as of the date hereof.

 

Investor Contacts:

 

Thierry Chauche, Chief Financial Officer
tchauche@proventionbio.com

 

Brendan Strong

Argot Partners

Proventionbio@argotpartners.com

212-600-1902

 

Media Contact:

 

Kaelan Hollon, VP of Communications
khollon@proventionbio.com
202-421-4921

 

 

 

 GRAPHIC 3 ex99-1_001.jpg begin 644 ex99-1_001.jpg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end EX-101.SCH 4 prvb-20221004.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 5 prvb-20221004_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] Entity Information, Former Legal or Registered Name EX-101.PRE 6 prvb-20221004_pre.xml XBRL PRESENTATION FILE XML 7 R1.htm IDEA: XBRL DOCUMENT v3.22.2.2
Cover
Oct. 04, 2022
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Oct. 04, 2022
Entity File Number 001-38552
Entity Registrant Name Provention Bio, Inc.
Entity Central Index Key 0001695357
Entity Tax Identification Number 81-5245912
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 55 Broad Street
Entity Address, Address Line Two 2nd Floor
Entity Address, City or Town Red Bank
Entity Address, State or Province NJ
Entity Address, Postal Zip Code 07701
City Area Code (908)
Local Phone Number 336-0360
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common stock, $0.0001 par value per share
Trading Symbol PRVB
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Entity Information, Former Legal or Registered Name Not Applicable
XML 8 form8-k_htm.xml IDEA: XBRL DOCUMENT 0001695357 2022-10-04 2022-10-04 iso4217:USD shares iso4217:USD shares 0001695357 false 8-K 2022-10-04 Provention Bio, Inc. DE 001-38552 81-5245912 55 Broad Street 2nd Floor Red Bank NJ 07701 (908) 336-0360 Not Applicable false false false false Common stock, $0.0001 par value per share PRVB NASDAQ false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2.2 html 1 24 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://proventionbio.com/role/Cover Cover Cover 1 false false All Reports Book All Reports form8-k.htm ex99-1.htm prvb-20221004.xsd prvb-20221004_lab.xml prvb-20221004_pre.xml http://xbrl.sec.gov/dei/2022 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "form8-k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "form8-k.htm" ] }, "labelLink": { "local": [ "prvb-20221004_lab.xml" ] }, "presentationLink": { "local": [ "prvb-20221004_pre.xml" ] }, "schema": { "local": [ "prvb-20221004.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/srt/2022q3/srt-sup-2022q3.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022q3/us-gaap-sup-2022q3.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 60, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 24, "memberCustom": 0, "memberStandard": 0, "nsprefix": "PRVB", "nsuri": "http://proventionbio.com/20221004", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form8-k.htm", "contextRef": "From2022-10-04to2022-10-04", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://proventionbio.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form8-k.htm", "contextRef": "From2022-10-04to2022-10-04", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://proventionbio.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://proventionbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://proventionbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://proventionbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://proventionbio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://proventionbio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://proventionbio.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://proventionbio.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://proventionbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://proventionbio.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://proventionbio.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://proventionbio.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://proventionbio.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://proventionbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://proventionbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://proventionbio.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://proventionbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://proventionbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://proventionbio.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://proventionbio.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://proventionbio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://proventionbio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://proventionbio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://proventionbio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://proventionbio.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://proventionbio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://proventionbio.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://proventionbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://proventionbio.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://proventionbio.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://proventionbio.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://proventionbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://proventionbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://proventionbio.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://proventionbio.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://proventionbio.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInformationFormerLegalOrRegisteredName": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Former Legal or Registered Name of an entity", "label": "Entity Information, Former Legal or Registered Name" } } }, "localname": "EntityInformationFormerLegalOrRegisteredName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://proventionbio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://proventionbio.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://proventionbio.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://proventionbio.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://proventionbio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://proventionbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://proventionbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://proventionbio.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://proventionbio.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://proventionbio.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://proventionbio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://proventionbio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://proventionbio.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://proventionbio.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://proventionbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://proventionbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://proventionbio.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://proventionbio.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://proventionbio.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://proventionbio.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://proventionbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://proventionbio.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://proventionbio.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" } }, "version": "2.1" } ZIP 15 0001493152-22-027755-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-22-027755-xbrl.zip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